You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors

Authors

  • Juan Chen Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of ChinaDepartment of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles
  • Jia-Si Liu Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China PubMed articlesGoogle scholar articles
  • Jun-Yan Liu Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles
  • Lei She Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles
  • Ting Zou National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles
  • Fan Yang Department of Physiology, School of Basic Medical Sciences, Shandong University, Jinan, Shandong, People's Republic of China PubMed articlesGoogle scholar articles
  • Xiang-Ping Li Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of ChinaThe Hunan Institute of Pharmacy Practice and Clinical Research, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles
  • Zhan Wang Lung Cancer and Gastrointestinal Unit, Department of Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles
  • Zhaoqian Liu Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of ChinaInstitute of Clinical Pharmacology, Engineering Research Center for applied Technology of Pharmacogenomics of Ministry of Education, Central South University, Changsha, Hunan, People's Republic of China PubMed articlesGoogle scholar articles

Citation

Chen J, Liu J, Liu J, et al
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
Journal for ImmunoTherapy of Cancer 2024;12:e009399. doi: 10.1136/jitc-2024-009399
Online issue publication 
July 11, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.